81. DUPHALAC DRY In portal systemic encephalopathy administration of large doses of Duphalacresults in a significant reduction in the pH of the colonic contents. http://home.intekom.com/pharm/schering/duph-dry.html

INDICATIONS CONTRA-INDICATIONS DOSAGE SIDE-EFFECTS PREGNANCY OVERDOSE IDENTIFICATION PATIENT INFORMATION DUPHALAC DRY SCHEDULING STATUS: Not scheduled PROPRIETARY NAME (and dosage form): DUPHALAC DRY Crystalline powder COMPOSITION 10 g of Duphalac Dry contains 10 g lactulose (4-0-beta-D-galactopyranosyl-D-fructofuranose) (a maximum of 0,25 g galactose and 0,2 g lactose). PHARMACOLOGICAL CLASSIFICATION A. 11.5 Laxatives. PHARMACOLOGICAL ACTION Duphalac is a synthetic disaccharide of fructose and galactose, which is not split into its monosaccharide constituents in the small intestine due to the lack of a specific enzyme. It reaches the colon unchanged where it is broken down by the saccharolytic flora into organic acids, such as lactic acid and acetic acid, acids formed in the colon under physiological conditions. Due to this local osmotic effect in the colon, water is retained, the faecal mass softened and normal colonic peristalsis restored. The mode of action differs from that of conventional laxatives. In portal systemic encephalopathy administration of large doses of Duphalac results in a significant reduction in the pH of the colonic contents. Lowering the pH promotes conversion of non-ionised ammonia into ionised form. The latter form being non-absorbable leads to reduction of absorption of ammonia from the intestine into the portal circulation and may even promote the excretion of ammonia from the circulation into the faeces.

82. Untitled Document Acute and chronic portal systemic encephalopathy. Lamictal (UK US) ManufacturerGlaxo Wellcome Treatment Class Psychopharmacologic and Neurologic (CNS) http://www.cgi-installer-software.com/sites/hospitalweb/html/Pharmaceutical data

PHARMACEUTICAL DATABASE L Drugs are listed alphabetically by manufacturer 's product name. (Note: Some of these drugs may not be available in the United Kingdom.) The following information is not intended as a medical advice. While every attempt is made to be accurate, we do not assume responsibility for any mistakes, omissions or the use of the pharmaceutical products listed in this database. Contact: admin@hospitalweb.co.uk RETURN TO HOSPITAL WEB DIRECTORY OF PHARMACEUTICAL COMPANIES A ... X Y Z (Click on letter to go the drugs starting with that letter.) ALLERGIES. CARDIOVASCULAR. CENTRAL NERVOUS SYSTEM. CONTRACEPTION. ... SKIN. Labosept. (UK) Manufacturer: L.A.B. Treatment Class: Ear, Nose, Throat. Oropharyngeal. Indication: Mouth and throat infections. Lacabiotal. (UK) Manufacturer: Sevier. Treatment Class: Ear, Nose, Throat. Oropharyngeal. Indication: Infections of the upper respiratory tract. Lacre-lube. (UK) Manufacturer: Allergan. Treatment Class: Eye. Ocular lubricants. Indication: Eye lubricant, corneal protection.

83. Untitled Document Acute and chronic portal systemic encephalopathy. Lactugal. (UK) Manufacturer Galen. Treatment Class Gastrointestinal Tract , Laxative. http://www.cgi-installer-software.com/sites/hospitalweb/html/Pharmaceutical data

PHARMACEUTICAL DATABASE GASTROINTESTINAL (Note: Some of these drugs may not be available in the United Kingdom.) The following information is not intended as a medical advice. While every attempt is made to be accurate, we do not assume responsibility for any mistakes, omissions or the use of the pharmaceutical products listed in this database. Contact: admin@hospitalweb.co.uk RETURN TO HOSPITAL WEB DIRECTORY OF PHARMACEUTICAL COMPANIES A ... X Y Z (Click on letter to go the drugs starting with that letter.) ALLERGIES. CARDIOVASCULAR. CENTRAL NERVOUS SYSTEM. CONTRACEPTION. ... SKIN. Aciphex (US). Manufacturer: Eisai Inc. Treatment class: Gastrointestinal. Indication: Gastroesophageal reflux disease (GERD), and duodenal and gastric ulcers (proposed). Actigall (US). Manufacturer: Summit Pharmaceuticals. Treatment class: Gastrointestinal. Indication: radiolucent, noncalcified gallstones. Aggrastat (US). Manufacturer: Merck Treatment class: Cardiovascular Indication: Unstable angina and non-Q-wave myocardial infarction Aggrenox (US).

84. SK+F Pharmaceuticals Ltd.[Laxitol] Acute and chronic portal systemic encephalopathy. In portal systemicencephalopathy The dose should be adjusted according to the severity of the http://www.skfbd.com/product/laxitol.html

CONTACT US SITE MAP HOME Product- Locally Manufactured Product- Laxative Laxitol Lactitol monohydrate powder Prescribing Information DESCRIPTION INDICATIONS Constipation Acute and chronic portal systemic encephalopathy. DOSAGE AND ADMINISTRATION Lactitol can be mixed with hot or cold beverages, puddings etc. Dosage will require adjustment to obtain one daily bowel movement in constipated patients and two daily bowel movements in patients with portal systemic encephalopathy. For taking fraction doses (e.g. 2.5or 5 g) of presented 10g Lactitol, the whole 10g should be dissolved in water. Half of the solution for 5 g and one fourth for 2.5 g respectively should be taken. The rest of the solution should be discarded. In constipation Adult: The initial daily dosage should be 20 g taken in a single dose with the morning or evening meal and subsequently adjusted to produce 1 soft stool daily (dose of 10 g daily may be sufficient). Children: The mean dosage is 0.25 g/kg body weight daily.

85. Encephalopathy-drugs.html Mental state gradation, portal systemic encephalopathy index (PSEI), ABSTRACTBACKGROUND Portal systemic encephalopathy (PSE) is a complex http://www.indiana.edu/~pietsch/encephalopathy-drugs.html

go to Shufflebrain main menu Drug Therapy for Encephalopathy web contact: pietsch@indiana.edu A literature search at Indiana University, Bloomington, Indiana. The following MEDLINE items were compiled by SilverPlatter and are presented here with their generous co-operation and permission. ( See SilverPlatter's Worldwide Library for bibliographic search information Record 1 of 55 in MEDLINE EXPRESS (R) 1999/01-1999/02 TITLE: [Thiamine treatment today] AUTHOR(S): Tallaksen-CM; Bovim-G ADDRESS OF AUTHOR: Nevrologisk avdeling, Rikshospitalet, Oslo. SOURCE (BIBLIOGRAPHIC CITATION): Tidsskr-Nor-Laegeforen. 1998 Oct 20; 118(25): 3946-9 INTERNATIONAL STANDARD SERIAL NUMBER: 0029-2001 LANGUAGE OF ARTICLE: NORWEGIAN; NON-ENGLISH ABSTRACT: This article reviews some of the established data on thiamin and the most common symptoms of deficiency. Guidelines for appropriate therapy are offered. Thiamin or vitamin B1 was among the first vitamins to be discovered. Beriberi was the first disease to be associated with thiamin deficiency, and Wernicke's encephalopathy was shown to respond to thiamin treatment a few years later. However, thiamin treatment remains inadequate or delayed. Treatment is efficient in the early stages, but delays often causes permanent damage. It is important that all physicians are aware of what patients are susceptible to develop thiamin deficiency and that they recognize the symptoms as early as possible. MEDLINE ACCESSION NUMBER: 99048032 Record 2 of 55 in MEDLINE EXPRESS (R) 1999/01-1999/02

86. Virtual Cancer Centre - Drugs Portal systemic encephalopathy 30-45ml 3-4 times daily. - Initially themedication may be given more often, even up to hourly, but this will be reduced http://www.virtualcancercentre.com/drugs.asp?drugid=85&type=generic

87. Unit 4 including portal hypertension and portal systemic encephalopathy. Frank Papopolous GI bleeding and Hepatic encephalopathy associated with Liver http://mtsu32.mtsu.edu:11019/N460/unit4.html

UNIT IV LIFE THREATENING HEALTH DEVIATIONS INVOLVING METABOLISM: GASTROINTESTINAL FUNCTION LEARNING OBJECTIVES: Describe the physiological processes of gastrointestinal functioning and hepatic metabolism. Analyze clinical manifestations (normal and abnormal) associated with gastrointestinal and hepatic function i.e.; physical assessment, laboratory data, radiographic studies. Describe the pathophysiology, clinical manifestations and management of a client with an upper gastrointestinal bleed. Develop an appropriate plan of care for the client with a upper GI bleed, listing applicable nursing diagnoses, evaluation criteria, and interventions. Differentiate the etiologies of acute and chronic hepatic failure. Describe the pathophysiology, clinical manifestations and management of a client with hepatic dysfunction/failure, including portal hypertension and portal- systemic encephalopathy. Develop an appropriate plan of care for the client with hepatic dysfunction/failure, including portal hypertension and portal-systemic encephalopathy, listing applicable nursing diagnoses, evaluation criteria, and interventions. Identify potential nursing research areas in the prevention and management of life threatening health deviations affecting gastrointestinal functioning.

88. Gammagard Settlement Notice - Definitions Of Qualifying Conditions Portal Systemic encephalopathy ( PSE ) is a brain syndrome due to liver disease.Proof of this condition shall require all of the following http://www.ssem.com/gammagard/settlement/notice/attachmenta.html

CLICK HERE Return to Settlement Notice ATTACHMENT A DEFINITIONS OF QUALIFYING CONDITIONS Settlement class members should note that the following medical terms necessarily involve technical words. You should consult your doctor about these medical conditions. (A) Ascites. Ascites is an abdominal fluid collection within the peritoneal cavity. Proof of this condition shall require all of the following: an abdominal ultrasound or computerized tomography ("CT") scan of the abdomen to confirm that ascitic fluid is present; an abdominal paracentesis that removes at least 500 milliliters of ascitic fluid; and paracentesis fluid analysis with all of the following tests and all of the following results: TEST RESULT Cytology Negative for malignancy Polymorphonuclear (PMN) cell count Serum-ascites albumin gradient (SAAG) (defined as ascites albumin subtracted from serum albumin) Protein Bacterial culture at bedside in blood culture bottles, aerobic and anaerobic No growth Mycobacterial culture No growth Amylase Ascites amylase less than serum amylase The following conditions are possible "Alternative Causes" of Ascites in a patient with or without HCV: malignancy, primary or metastatic; protein-losing enteropathy; heart failure; ruptured viscus; tuberculosis; dengue, cholera or schistosomiasis; pancreatitis; kidney failure; chlamydia infection; fungal or parasitic infection in the peritoneum; peritonitis (other than spontaneous bacterial peritonitis); Budd Chiari syndrome; portal vein thrombosis or occlusion (intra or extra luminal); use of amiodarone; exposure to or ingestion of hepatotoxin; or consumption of significant amounts of alcohol (consumption of enough alcohol for a sufficient period of time to produce, either separately or in a synergistic fashion with HCV, the progression of liver damage).

89. Alcoholism: Clinical And Experimental Research - UserLogin esophageal variceal bleeding, portal systemic encephalopathy), (73%)patients had ascites, and five (15%) had portal systemic encephalopathy. http://www.alcoholism-cer.com/pt/re/alcoholism/fulltext.00000374-200405000-00013

LWWOnline LOGIN eALERTS REGISTER ... Ahead of Print You are attempting to access protected content. To access this content please login using an established account or create/activate an account. If you have already created/ activated an online account, please login below: User Name: Password: Note: passwords are CASE SENSITIVE If you are a new user or guest visiting an LWWonline site for the first time, please complete the new account setup process to view or purchase content. Forgot your password? Subscribe Renewal Information Subscribe to RSS feed utrdc-pt02 Release 4.0

90. Dr. Huma Qureshi---Paper Presentation Biochemical aspects of portal systemic encephalopathy XVI Biennial ConferencePakistan Medical Association Karachi, 2327th Nov. 1984 http://www.pmrc.org.pk/humaprestn.htm

PAPERS PRESENTED IN THE NATIONAL AND INTERNATIONAL MEETINGS 1. “Intra-hepatic choledochal cyst” surgical conference of Civil Hospital and Dow Medical College, Karachi (1980) 2. “Osteomalacia” Orthpaedic Conference of Civil Hospital and Dow Medical College, Karachi (1980) 3. “Peptic Ulcer Disease, Diagnosis and treatment”. 19 th Annual Symposium, Jinnah Postgraduate Medical Centre, Karachi. 19-24th, 1981 4. “Pattern of admission in general surgical unit” 19 th Annual Symposium of Jinnah Postgraduate Medical Centre, Karachi. 19-24 Dec 1981 5. “Value of emergency endoscopy in upper G.I. bleeding” First Annual Seminar of Civil Hospital and Dow Medical College, Karachi, March 1982 6. “Clinical aspects of hepatic coma”. Pakistan Medical Research, Research Congress, Peshawar 6-7 th November, 1982 7. “Profile of renal function tests in controls and Hepatic disease" Pakistan Medical Research Council, Research Congress, Peshawar 6th-7th November, 1982 8. “Nutritional aspects in hepatic coma” Pakistan Medical Research Centre, Research Congress, Peshawar 5-7 Nov.1982

91. Dr.Huma Qureshi---Publications and Renal functions in portal systemic encephalopathy (PSE) Pak. Qureshi H., Zuberi SJ Management of acute portal systemic encephalopathy . http://www.pmrc.org.pk/humapub.htm

PUBLICATION (National - International Original Articles: 1. Qureshi, H. and Zuberi, S.J. "Diagnostic value of sigmoidoscopy". Pakistan Journal of Medical Research. 21:59, 1982. Junaid, I., Qureshi, H., Hassan, A. and Ahmad, M. "Pattern of admission in a general surgical unit, Journal of Pakistan Medical Association, 1982; 32:187-190. Nizami, F., Qureshi. H., Shahid, A., Hassan, R. and Zuberi, S.J. "Nutritional Aspects of Hepatic Coma". Journal of Pakistan Medical Association, 33:162, 1983. Shahid, A., Qureshi, H., Nizami, F. and Zuberi, S.J. "Electrolytes in liver disease – preliminary study". Journal of Pakistan Medical Association.1983; 32:289-293. Shahid, A. Qureshi, H. and Zuberi, S.J. "Disorders of Renal functions in liver disease". Pakistan Journal of Medical Research. 1983; 22:79. 6. Shahid, A., Qureshi, H. and Zuberi, S.J. Amonia intoxiocation in Hepatic coma Journal of Pakistan Medical Association. 1984; 34:9. Shahid, A., Qureshi, H. and Zuberi, S.J. Disorders of renal function in hepatic coma. Journal of Pakistan Medical Association. 1984; 34:28.

92. The Medical Algorithms Project, Chapter1 The PSE (Portal Systemic encephalopathy) Index of Conn et al. Audiology.Indications for Audiologic Evaluation in Children http://www.medal.org/visitor/www/inactive/ch17.aspx

Not Logged In The Medical Algorithms Project Chapter : ch17. Neurology Only the first few algorithm links in this page are active, as indicated by the icons. To have access to all the spreadsheets, please register (free) and login with your username. Coma Scales Glasgow Coma Scale Children's Coma Scale (Modified Glasgow Coma Scale, Adelaide Coma Scale, Paediatric Coma Scale) Blantyre Coma Scale for Young Children COHMC Coma Scale for Brain-Injured Children ... The Children's Coma Score from Children's Memorial Hospital for Young Children Multiple Sclerosis (MS) Magnetic Resonance Imaging (MRI) Criteria of Barkhof et al for a Brain Abnormality Associated with Clinically Definite Multiple Sclerosis Prognostic Factors in Patients with Multiple Sclerosis Criteria for Demonstrating Dissemination of CNS Lesions in Time on MRI Scan Diagnostic Criteria for Multiple Sclerosis from the International Panel on the Diagnosis of Multiple Sclerosis Arteriovenous Malformations (AVM) and Intracranial Aneurysms Spetzler-Martin Scale for Grading Arteriovenous Malformations (AVM) of the Brain Risk Factors of Janardhan et al for Morbidity After Intervention for an Incidental Intracranial Aneurysm Risk Factors of Rinkel et al for Rupture of Intracranial Saccular Aneurysms Simple Risk Equation of Kondziolka et al for Hemorrhage from an Arteriovenous Malformation Shi-Chen Scale for Grading an Intracranial Arteriovenous Malformation (AVM) Subarachnoid Hemorrhage Hunt and Hess Grading System for Subarachnoid Hemorrhage World Federation of Neurologic Surgeons Grading System for Subarachnoid Hemorrhage

93. IM Abstract 39-5 Case Reports 10 Portal Systemic encephalopathy Presenting with Dressing and Constructional Apraxia.We report a case with portal systemic encephalopathy who presented with http://www.naika.or.jp/im/im39/ab3905/c390510.html

Home Table of Issues Vol.39 No.5 Portal Systemic Encephalopathy Presenting with Dressing and Constructional Apraxia We report a case with portal systemic encephalopathy who presented with dressing and constructional apraxia and subtle weakness of the left hand. We initially suspected a cerebrovascular attack in the right cerebral hemisphere, but brain T1-weighted magnetic resonance (MR) imaging revealed high intensity in the basal ganglia and hyperammonemia was detected. We performed abdominal MR angiography, which visualized an intrahepatic portal systemic shunt. Cerebral blood flow, measured by xenon-enhanced computed tomography, was decreased in the bilateral, but more dominantly right-sided, parietal watershed regions. We speculate that these boundary territories might be susceptible to damage by toxic metabolites of hepatic encephalopathy. (Internal Medicine 39: 419-423, 2000) Takeshi Kanda, Shigeru Nogawa, Kazuhiro Muramatsu, Atsuo Koto and Yasuo Fukuuchi From the Department of Neurology, Keio University, Tokyo Received for publication June 29, 1999; Accepted for publication November 1, 1999 Home Table of Issues Vol.39 No.5

94. Alcohol Health & Research World: Liver-brain Relations In Alcoholics - Special F Portal systemic encephalopathy (PSE), the most common form of hepatic encephalopathy,is a cerebral complication of cirrhosis that causes disruption of http://www.findarticles.com/p/articles/mi_m0847/is_n2_v14/ai_9858955

@import url(/css/us/style1.css); @import url(/css/us/searchResult1.css); @import url(/css/us/articles.css); @import url(/css/us/artHome1.css); Advanced Search Home Help IN free articles only all articles this publication Automotive Sports 10,000,000 articles - not found on any other search engine. FindArticles Spring 1990 Content provided in partnership with 10,000,000 articles Not found on any other search engine. Related Searches Alcohol / Physiological aspects Hepatic encephalopathy / Complications Liver diseases / Complications Alcoholics / Psychological aspects Featured Titles for AAACN Viewpoint ABNF Journal, The AIDS Treatment News AMAA Journal ... View all titles in this topic Hot New Articles by Topic Automotive Sports Top Articles Ever by Topic Automotive Sports Liver-brain relations in alcoholics - Special Focus: Alcohol and the Brain Spring, 1990 by Amelia M. Arria Ralph E. Tarter David H. Van Thiel Save a personal copy of this article and quickly find it again with Furl.net. It's free! Save it. Liver-Brain Relations in Alcoholics The central nervous system (CNS) can be adversely affected by a damaged liver. Evidence suggests that impaired liver function, resulting from alcohol abuse as well as other causes, can produce subtle but measurable cognitive deficits (Tarter et al. 1984a). It is well established that chronic alcohol consumption in animals has a direct toxic effect on the brain (Freund 1985). This effect, however, does not appear to explain the spectrum of cognitive deficits that commonly are observed in alcoholics.

95. Alcohol Health & Research World: Glossary - Special Focus: Alcohol And The Brain Portal systemic encephalopathy The most common form of hepatic encephalopathy.This cerebral complication of liver cirrhosis disrupts consciousness, http://www.findarticles.com/p/articles/mi_m0847/is_n2_v14/ai_9858971

@import url(/css/us/style1.css); @import url(/css/us/searchResult1.css); @import url(/css/us/articles.css); @import url(/css/us/artHome1.css); Advanced Search Home Help IN free articles only all articles this publication Automotive Sports 10,000,000 articles - not found on any other search engine. FindArticles Spring 1990 Content provided in partnership with 10,000,000 articles Not found on any other search engine. Related Searches Alcoholism / Terminology Brain / Anatomy Neurology / Terminology Featured Titles for AAACN Viewpoint ABNF Journal, The AIDS Treatment News AMAA Journal ... View all titles in this topic Hot New Articles by Topic Automotive Sports Top Articles Ever by Topic Automotive Sports Glossary - Special Focus: Alcohol and the Brain - glossary Spring, 1990 Save a personal copy of this article and quickly find it again with Furl.net. It's free! Save it. GLOSSARY Action potential: The wave of electrical impulses traveling through a neuron to the end of the axon. Adenylate cyclase: The enzyme that produces the second messenger cAMP. Agonist: A substance that activates a receptor.

96. ITU GasLink Guidelines For Fulminant Hepatic Failure And á manage associated problems (ARF, encephalopathy, GI bleeding) Blake A Jones.¤ Portal Systemic encephalopathy. ¤ Hepatic Failure. Cochrane Library. http://www.clinicalschool.swan.ac.uk/wics/itugl/liv.htm

97. Karger Publishers and neomycin in the treatment of chronic portal systemic encephalopathy. tests in the assessment of mental state in portal systemic encephalopathy. http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowFulltext&ProduktNr=

98. FindLaw For Legal Professionals - Case Law, Federal And State Resources, Forms, Without Lactulose, a person with portal systemic encephalopathy could slip intoa coma caused by excess ammonia in the bloodstream. http://caselaw.lp.findlaw.com/cgi-bin/getcase.pl?court=7th&navby=case&no=981154

99. Utility Of P300 Auditory Event Related Potential In Detecting Cognitive Dysfunct Conn HO, Lieberthal MM Pathogenesis of portal systemic encephalopathy . In The hepatic coma syndromes and lactulose. Baltimore Williams and Wilkins http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2001;volume=49;iss

100. ÃÀÑÒÐÎÝÍÒÅÐÎËÎÃÈß- ÏÐÈËÎÆÅÍÈÅ Ê CONSILIUM MEDICUM :: Lactitol or la?tulose in the treatment of chronic hepatic encephalopathy; vegan and meat protein diets in mild chronic portal systemic encephalopathy. http://www.consilium-medicum.com/media/gastro/04_01/20.shtml

Òîì 06/N 1/2004  òêàíÿõ è æèäêîñòÿõ àììèàê ñóùåñòâóåò â âèäå èîíà àììîíèÿ NH â ðàâíîâåñèè ñ íåáîëüøîé êîíöåíòðàöèåé íåèîíèçèðîâàííîãî àììèàêà NH b Ïåðå÷èñëåííûå èçìåíåíèÿ, ïðîèñõîäÿùèå â ãîëîâíîì ìîçãå ïðè ãèïåðàììîíèåìèè, ïðèâîäÿò ê êëèíè÷åñêèì ïðîÿâëåíèÿì, îáîçíà÷àåìûì òåðìèíîì "ïå÷åíî÷íàÿ ýíöåôàëîïàòèÿ" (ÏÝ). Ñëåäóåò îòìåòèòü, ÷òî â ïàòîãåíåçå ÏÝ ðàññìàòðèâàåòñÿ ó÷àñòèå åùå öåëîãî ðÿäà ôàêòîðîâ (ìåðêàïòàíû, ôåíîëû, íàêîïëåíèå ìàðãàíöà è äð.). Îäíàêî ñ òî÷êè çðåíèÿ îáîñíîâàííîñòè è ýôôåêòèâíîñòè ïàòîãåíåòè÷åñêîãî ïîäõîäà ê ëå÷åíèþ â íàñòîÿùåå âðåìÿ ïðåäïî÷òåíèå îòäàåòñÿ ñðåäñòâàì, íàïðàâëåííûì íà êóïèðîâàíèå ãèïåðàììîíèåìèè. Âðîæäåííûé äåôèöèò ôåðìåíòîâ îðíèòèíîâîãî öèêëà õàðàêòåðèçóåòñÿ ÏÝ è ãèïåðàììîíèåìèåé. Äåôèöèò êàðáàìîèëôîñôàòñèíòåòàçû I ïðèâîäèò ê çíà÷èòåëüíîé ãèïåðàììîíèåìèè è ñàìûì òÿæåëûì ïðîÿâëåíèÿì. Ñòåïåíü âûðàæåííîñòè ãèïåðàììîíèåìèè è ÏÝ íèæå ïðè íåäîñòàòî÷íîñòè äðóãèõ ôåðìåíòîâ îðíèòèíîâîãî öèêëà. Ðèñ. 3. Ïîâûøåíèå îñìîëÿëüíîñòè ïðè ãèïåðàììîíèåìèè: 1H-ìàãíèòíî-ðåçîíàíñíàÿ ñïåêòðîñêîïèÿ ó çäîðîâûõ ëèö (A), áîëüíûõ öèððîçîì ïå÷åíè ñ ëàòåíòíîé (B) è êëèíè÷åñêè ìàíèôåñòíîé ïå÷åíî÷íîé ýíöåôàëîïàòèåé I–II ñòåïåíè. (C) D.Haussinger è ñîàâò. Gastroenterology 1994; 107: 1475–80.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-100 of 102    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20